Frédéric Chereau

Frédéric Chereau

Board member

Frederic Chereau currently serves as President and Chief Executive Officer of LogicBio Therapeutics. From 2014 to 2015, Mr. Chereau was President and Chief Operating Officer of aTyr Pharma (LIFE). During his tenure, the company advanced multiple programs to clinical stage and successfully completed private financing and an IPO. Prior to that, Mr. Chereau was Senior Vice President and Angioedema Franchise Lead at Shire (SHPG), where he defined and oversaw the execution of the global strategy for the franchise, positioning it as the leader on its market. From 2008 to 2012, as President and Chief Executive Officer of Pervasis Therapeutics, he led the company through key strategies leading up to the acquisition of the company by Shire. Before Pervasis, Mr. Chereau worked at Genzyme from 1999 to 2008, where he held roles with increasing responsibility, initially within Genzyme France and Genzyme Europe, and achieved the position of Vice President and General Manager of the Cardiovascular Business Unit at Genzyme Corporation. Prior to Genzyme, he started his career at Hemotech, where he held sales and marketing roles. Mr. Chereau serves as a member of the Comite Strategique d’Orientation at La Rochelle Business School. He holds a B.S. in Physics from Paris University, received his master’s degree in management from La Rochelle Business School in France, and received an MBA from INSEAD, Fontainebleau, France and Singapore.